July 18, 2013 — Two reports from AmericanEHR Partners, based on a survey of nearly 1,400 physicians, suggest that tablets are of greater use for clinical purposes than smart phones.
July 18, 2013 — In a study of more than 2,000 adults, researchers found that two MRI (magnetic resonance imaging) measurements of the abdominal aorta — the amount of plaque in the vessel and the thickness of its wall — are associated with future cardiovascular events, such as a heart attack or stroke. Results of the study are published online in the journal Radiology.
July 18, 2013 — Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE mark approval for the Guidezilla guide extension catheter.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Welch Allyn announced the availability of two connectivity-ready electrocardiograph devices in the United States. The Welch Allyn CP 150 offers flexible report formatting, intuitive design and functionality in addition to administering patient tests and managing information via a touch screen, color display. The Welch Allyn CP 50 offers the speed and power of a fully-featured ECG in a compact, portable size. Designed for use in settings where flexibility and efficiency are of utmost importance, both devices administer patient tests at the push of a button. Each can also interface with the Welch Allyn CardioPerfect Workstation to connect, manage and share patient information.
The first-ever presentation at a medical conference using hologram technology instead of traditional video projection screen took place July 1 at the American Society of Echocardiography’s (ASE) 2013 scientific sessions. The innovative presentation was used to drive home the advances in technology that are going to completely reshape cardiac ultrasound and medical imaging over the next few years.
ImaCor Inc. announced the implementation of the 24/7 hTEE Clinical Support Program.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
American Society of Echocardiography (ASE) President Benjamin Byrd III, M.D., FASE, explains some of the recent trends ...
DAIC Editor Dave Fornell highlights some of the biggest trends and most innovative technology discussed during the ...
July 15, 2013 — Leonhardt Ventures and Core Manufacturing LLC have announced a new partnership to manufacture and bring to market a lineup of medical technologies.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
July 15, 2013 — Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental new drug application (sNDA) for Xarelto (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome (ACS).
Shore University Medical Center is one of only a handful of hospitals in the country offering the recent U.S. Food and Drug Administration (FDA)-approved Lariat Suture Delivery Device procedure. Electrophysiologists and interventional cardiologists perform this innovative procedure to help prevent stroke in patients who suffer from atrial fibrillation and are unable to take blood thinners.
The lag in FDA approval time for major medical innovations has come increasing concerns about the ability of the United States to remain at the forefront of research, especially in light of stringent FDA policies regarding clinical trials and device approval.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
July 12, 2013 — A Chicago native living in southern California was the first patient at Scripps Health to receive a MitraClip as part of the clinical outcomes assessment of the MitraClip Percutaneous Therapy for High Surgical Risk Patients (COAPT) trial.
July 12, 2013 — Micell Technologies Inc. received CE mark approval for its MiStent sirolimus-eluting absorbable polymer coronary stent system. The MiStent SES is unique in providing local drug delivery both during and after the period of polymer absorption, thereby eliminating long-term polymer exposure, a potential cause of delayed healing and late adverse events.
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation has entered into a definitive agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, for $275 million in cash. The company expects to close the transaction in the second half of 2013, subject to customary closing conditions.